

1 **A preliminary remark**

2 medRxiv: "This article is a preprint and has not been peer-reviewed. It reports new medical research that has  
3 yet to be evaluated and so should not be used to guide clinical practice.  
4

5 Our data analysis suggests that known studies and treatments should be reconsidered: chemoprevention,  
6 hormonal replacement therapy, long-term endocrine therapies, lymph node dissections, and the 4:1 rule of  
7 local recurrences were questioned. We would really appreciate it, if readers could point out errors, unclear  
8 wording, missing aspects, insufficient literature quotes and other improvements. Bookmarks and consecutive  
9 line numbering should facilitate short notes like "line x: wrong", in the sense of an open science accessible to  
10 everyone via medRxiv. Thank you in advance. The authors  
11

12 Breast cancer: Emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer  
13 registry data

14 Jutta Engel<sup>1,2</sup>, Renate Eckel<sup>1</sup>, Simone Schrodi<sup>2</sup>, Kathrin Halfter<sup>1</sup>, Gabriele Schubert-Fritschle<sup>1,2</sup>,  
15 Dieter Hölzel<sup>1</sup>

16 <sup>1</sup>Munich Cancer Registry (MCR), Institute for Medical Information Processing, Biometry and  
17 Epidemiology (IBE), Ludwig-Maximilians-University (LMU), D-81377 Munich, Germany

18 <sup>2</sup>Munich Cancer Registry (MCR), Bavarian Cancer Registry - Regional Centre Munich (LGL)  
19 at the University Hospital of Munich  
20

21 Corresponding author:

22 Prof. Dr. Dieter Hölzel

23 Munich Cancer Registry

24 D-81377 München, Germany

25 hoe@ibe.med.uni-muenchen.de

26 Tel: ++49-89-8414875  
27

28 **Abbreviations**

29 AT neo-adjuvant systemic therapy

30 BC breast cancer

31 HR hormone receptor

32 (s)MET (secondary) metastases

33 MET-P metastasization process

34 LR local recurrence

35 (p)LN positive lymph node

36 (1st/2nd)PT (first/second) primary tumor/breast cancer

37 (d/c)TC (disseminated/circulating) tumor cell

38 TD tumor diameter

39 VD(T) volume doubling (time)

40 **Keywords:**

41 breast cancer, tumor initiation, tumor growth, local recurrence, lymph node, metastasis, adjuvant  
42 treatment, survival  
43

44 Body text: 6437 words

45 Abstract: 333 words

46 ~~References~~ This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 Figures: 3 (and 16 individual Figures)

## 48 **Abstract**

49 *Background:* A growing primary breast cancer (PT) can initiate local (LR), regional (pLN), and distant  
50 metastases (MET). Characteristics of these progressions such as initiation, frequency and duration of  
51 PT and MET growth describe principles of the MET process. They are bottlenecks through which  
52 molecular hypotheses and scientific terms for prediction and prognosis have to go.

53 *Methods:* Population-based data from the Munich Cancer Registry over 4 time periods since 1978  
54 with the most important prognostic factors and a follow-up up to this day are analyzed. With  
55  $n = 66.818$  patients, reliable data are obtained on initiation on METs, growth times und survival even  
56 in small subgroups. Together with results of clinical trials on prevention and adjuvant treatment (AT)  
57 principles of tumor growth, MET process and AT are summarized.

58 *Results:* The median growth periods for PT/ MET/LR/pLN result in 12,5/8,8/5/3,5 years. Even if 30%  
59 of METs only appear after 10 years of MET-free time, a delayed initiation or cascade like initiation of  
60 METs, e.g. from pLNs cannot be derived from the data. That is an immediate MET initiation principle  
61 by PT. The growth rate of the PT can vary by a factor of 10 or more and can be transferred to the  
62 MET. The coupling of the growth rates of PT/MET results in the principle of a nearly constant relation  
63 of about 1.4. Principles of AT are the 50% eradication of 1st and 2ndPT, the selective and partial  
64 eradication of bone and lung METs with successful ATs, which cannot be improved by extending the  
65 duration of ATs. These principles reveal that there is no convincing rationale for the currently  
66 accepted early risk of breast cancer by hormone replacement therapies, for long term endocrine ATs  
67 or cascade like initiation of METs.

68 *Conclusion:* A paradigm with nine principles for the MET process and ATs can be derived from real  
69 world data and clinical trials. The principles suggest alternative interpretations of well-known clinical  
70 trials and changes in treatments. The outlined MET process should be generalizable to all solid  
71 tumors.

## 72 **Introduction**

73 Biomedical research regularly increases the complexity of cancer. More and more details are  
74 emerging on the association with risk factors, the steps involved in carcinogenesis, and processes  
75 such as clonal evolution that ultimately result in genetically heterogeneous PTs.<sup>1-3</sup> Also the steps  
76 leading to metastasis, the MET-process (MET-P), are becoming increasingly differentiated.<sup>4,5</sup> By  
77 definition secondary metastases (sMET) are referred to as local recurrences (LRs), positive lymph  
78 nodes (pLNs), and distant METs. Primary and secondary BCs (1stPT/2ndPT) are also included because  
79 these may also be prevented and have the similar risk of initiating comparable sMETs.

80 Even though the molecular processes involved in the disease course of PTs and sMETs may be highly  
81 complex, these can nevertheless be described using only a few parameters and defined principles of  
82 METs and their treatment. The aim of this article is to elucidate initiation, growth, survival, and  
83 treatment effects of BC and sMET with real world data from the Munich Cancer Registry (MCR) which  
84 are basic conditions, the bottleneck through which molecular hypotheses and scientific terms for  
85 prediction and prognosis have to go.

## 86 **Methods**

87 The Munich Cancer registry (MCR) has data starting from 1978, it has been population-based for the  
88 currently underlying 4.9 million population since 1998, and is included in Cancer Incidence of Five  
89 Continents. Reliable data on changing adjuvant treatments (AT) and on locoregional disease  
90 manifestations from pathology reports such as hormone receptor status, tumor diameter (TD),  
91 number of pLN, Ki67 - since 2010 - and contralateral PT are available. All death certificates from the  
92 region have been incorporated and result in a follow-up to this day.

93 In the case of cancer-related death, approximately 70% of METs were recorded. Four time intervals  
94 have been distinguished since 1978 and the time trends of the successful ATs and the changing  
95 progressions are evaluated. Despite missing values, it is robust data with n=66.818 patients for the  
96 analysis of even small subgroups.

97 The relative survival is an estimate for tumor-specific survival and is calculated by dividing the overall  
98 survival after diagnosis by the survival observed in the general population with comparable age  
99 distribution.

100 Kaplan-Meier curves for the relative survival from diagnosis, for survival up to and after MET and  
101 with distributions of the MET-free survival time describe the relationships with prognostic and  
102 predictive factors. The relative survival is an estimate for tumor-specific survival and is calculated by  
103 dividing the overall survival after diagnosis by the survival observed in the general population with  
104 comparable age distribution.

105 METs account for the great majority of cancer-associated deaths, why this complex process needs to  
106 be better understood. With every millimeter of PT growth, further METs are initiated. Three growth  
107 phases are to be estimated, the time from occult MET growth to PT diagnosis, the MET-free time up  
108 to MET detection and survival afterwards. The distribution of the MET-free survival times is the shift  
109 of the distribution of the MET initiations before PT diagnosis if the same growth duration is assumed.  
110 The median time is an estimate of the growth duration of the METs.

111 So far, modeling has seldom been used in medicine to elucidate relationships. Processes are modeled  
112 with the distribution functions for the incidence of PTs and METs, the growth times and eradication  
113 rates. The effect of HRT with growth acceleration of prevalent PTs and a risk of new PTs or the long-  
114 term endocrine AT with a preventive and adjuvant effect are examples. Statistical analyses were  
115 performed by using SAS V 9.4 and R V 3.1.3.

## 116 **Results**

### 117 **Initiation of primary tumors and secondary foci**

118 Growing and evolutionarily developing PTs may have already disseminated circulating tumor cells  
119 (TC) and DNA (ctDNA) to form local or distant small foci through alterations in the tumor  
120 microenvironment.<sup>6,7</sup> Several cell types and signaling molecules are involved in promoting the  
121 epithelial-mesenchymal transition that allow TCs to disseminate. PTs can achieve MET-competence  
122 starting from about 1 mm TD<sup>4</sup> and initially a first MET-competent TC appears among many  
123 disseminated TCs.<sup>8</sup> They may remain local or may spread through lymphatic or hematogenous  
124 dissemination and initiate LRs, pLNs, and METs. Temporal aspects of initiation and growth of these  
125 sMETs are shown in Fig.1. In Fig.2A, possible sources and pathways of the initiating TCs are outlined  
126 and some results for pT1c- and pT2-PTs are arranged in Fig.2B. Growing PTs are associated with poor  
127 prognoses (Fig.2C). Until R0-resection, all TCs that can initiate sMETs are disseminated. Only  
128 dormancy could delay the onset. In the form of a liquid biopsy, circulating TCs and ctDNA can be  
129 detected when diagnosing a BC, although they are very rare and the sensitivity and specificity of the  
130 procedure is moderate.<sup>9,10</sup>

### 131 **Initiation of local recurrences**

132 When TCs migrate but remain close to the PT, they are able to initiate true LR. These usually occur  
133 within 3 centimeter (Fig.2A), the range of migrating TCs and the target area of the boost irradiation.  
134 The shared microenvironment of the PT and the LR forms a supporting niche providing particularly  
135 favorable growth conditions. This was shown in historical data from the NSABP-B-06 study with  
136 39.2% LR after breast conserving surgery without irradiation.<sup>11</sup> However, the term LR is inaccurate  
137 because LR like METs or pLNs can occur synchronously with PTs in about 18% and then are referred  
138 to as multifocal PTs.

139 In total, four types of LR can be distinguished: growing residual tumors from positive margins, true  
140 PT-near LRs, and independently initiated ipsilateral 2ndPT or multicentric PTs (Fig.1).<sup>12,13</sup> A fourth  
141 type may be foci that emerge through self-seeding.<sup>14,15</sup> Since these are initiated by TCs, which find  
142 their way back through circulation, they likely exhibit similar characteristics as true LRs but without  
143 the proximity to the PT (Fig.2A). In addition, this form of self-seeding can initiate contralateral foci. It  
144 can be assumed that tumor cell dissemination from PTs must have already been taking place for  
145 some time if LRs appear simultaneous to PTs. In parallel, as data from the MCR shows, initiation of  
146 pLNs becomes more likely with about 15% more pN+ findings for pT1-2m (multiple) PTs.<sup>16</sup>

#### 147 **Initiation of positive lymph nodes**

148 TCs can infiltrate LNs through lymphatic dissemination. This LN infiltration is also a stochastic process  
149 over time, with the number of pLNs representing discrete successive steps.<sup>17</sup> This process can be  
150 described by a simple Markov model with transition probabilities for each status with n pLN to reach  
151 the (n +1)pLN status by one millimeter growth. Fig.2B shows LN infiltration depending on pT-  
152 categories. In pT2-PTs more than half (26.2%) of the 46.5% pLNs are likely to have been infiltrated by  
153 TCs during growth up to pT1c. In the subgroup of hormone receptor (HR) positive non-advanced PTs,  
154 the percentage of patients with more than n pLNs can be described by Gompertz functions with 3  
155 parameters. Cumulated and complementary to 100%, Fig. 2E shows observed and fitted data for 0 to  
156 > 10pLN. For 0pLN results:  $y (\geq 0\text{pLN},\%) = 100 - 75.4 * \exp(-2.82 * \exp(-0.063 * \text{TD}))$  ( TD: 2 – 90mm).

157 In addition, large PTs can develop the required driver mutations at a later point in time but the  
158 infiltration process is not significantly affected. As the TD increases, the fraction with >10 pLNs  
159 increases at the expense of 0pLNs, the proportion of which varies between 0.05% and 1.75% per  
160 millimeter. However, the proportion with 1, 2 or 3 positive nodes is largely independent of the TD for  
161 larger PTs. In the 0pLN status, some of the PTs have begun to disseminate MET-competent TCs  
162 (Fig.2D). In PTs with negative sentinel LNs approximately 15.9% of isolated TC or micro-MET are  
163 detected, which corresponds to the proportion of 0pLN\* in Fig. 2E.<sup>18</sup> The risk of a MET for a patient  
164 with 0pLN status increases with the TD of the PT.

165 The sum of all pLNs that initiate growing and continuously disseminating PTs in 100 patients can also  
166 be described with a Gompertz function:  $\text{Sum (pLNs /TD)} = 646 * \exp(-3.91 * \exp(-0.041 * \text{TD}))$  (2  
167 <TD <90mm).<sup>17</sup> The asymptote of 646 pLNs is a biological characteristic, resulting from the  
168 proportion of subgroups 0pLN up to >10pLN in large tumors. Because of the maximum of about 30  
169 LNs the mean value for >10pLNs is 17, and is largely independent of the TD.

#### 170 **Initiation of metastases**

171 When are METs initiated? As described above, clinical findings on the effect of pT-category show that  
172 for pT1-PTs about 13% metastasize and two years after diagnosis tumor-related deaths are to be

173 expected after 15 years (Fig.2G). When comparing such results, the time reference of the cohort and  
174 therefore the ATs of the 2000s should be taken into account because progress has been made with  
175 successful innovations. If PTs are diagnosed at a later time point as pT2-PTs with a mean TD of  
176 28mm, the METs already initiated up to a tumor size of pT1c continued to grow and 25% new no  
177 longer eradicable METs are initiated after pT1c size (Fig.2B).<sup>19</sup>

178 In the pT2 category the proportion of advanced PTs has already reached 4.2% and the MET-free  
179 interval shortens to 4.2 years. The time scale of the MET-P in pT2-PTs illustrates that expediting the  
180 PT diagnosis avoids METs and results in a longer MET-free interval of 5.1 years. This constitutes a  
181 lead time effect for the subgroup with unavoidable METs, which are initiated up to a tumor size  
182 equivalent to pT1.

183 The initiation of MET is similar to that of LNs. At some point a TC succeeds in infiltrating a distant  
184 organ site, perhaps cooperatively as a homogeneous cluster or with other heterogeneous circulating  
185 TCs (polyclonal origin). Therefore, MET may have already been initiated in the pN0\* phase (Fig.2E).  
186 Indeed this can be seen in the 1pLN status as the doubling of the mortality. Thereafter, additional  
187 METs can be initiated sequentially by a PT, which can acquire further mutations in the meantime  
188 (Fig.1). Therefore, multiple METs in one or more organs and also in different pLNs can be genetically  
189 different.<sup>3,20</sup> In addition, different areas of a PT can already be assigned as source of TCs.<sup>21</sup>

#### 190 **Combinations of initiated sMETs**

191 If a PT disseminates MET-competent TCs in principle all three sMETs can be initiated. LR are more  
192 common than pLNs, which in turn are more common than METs, as TCs have to overcome additional  
193 lymphatic and hematogenous barriers, extravasation and colonization into organs.<sup>1</sup> All combinations  
194 of sMETs in any order are possible. In the absence of a variant, not only chance but also necessity  
195 may play a role, which may be related to MET organ-specific properties of TCs.<sup>22-24</sup> The competing  
196 initiation is illustrated in the 15-year relative survival which is 88.1/93.8/87.9/84.7% for pT1c and  
197 all / pN0 / 1pLN / 2pLNs respectively. The corresponding values for pT2 are 67.4 / 80.7 / 72.9 / 64.6%  
198 and demonstrate the high proportion of simultaneously initiated pLNs and METs.

#### 199 **Initiation of primary tumors**

200 The age-dependent incidence also reveals the initiation of 1stPTs<sup>19,25</sup>, which occurs years earlier  
201 according to the PTs growth durations. About 2% of patients have bilateral PTs which must be  
202 initiated nearly at the same time and then grew in parallel. The incidence of contralateral 2ndPT and  
203 PTs in prevention studies<sup>26</sup> show that year after year these PTs are diagnosed and must have been  
204 prevalent in the patient cohort according to the duration of the growth of PTs (Fig.2H). In high-risk  
205 groups<sup>27</sup> the incidence is increased, with a BRCA positive proportion of 60-80%, compared to

206 approximately life-long 12.4% of 1stPT in the normal population.<sup>25</sup> BC patients, in particular, are at  
207 least 3-5 times more likely to get a 2ndPT than the normal population.<sup>28</sup>

## 208 **Source and time of late MET initiations**

### 209 **Dormant TCs**

210 DTCs could be an inexhaustible source to initiate MET after PT removal.<sup>29-31</sup> The only argument for  
211 their existence is the detection of vital TCs in the bone marrow.<sup>32</sup> Such TCs exist and are a prognostic  
212 factor but probably not a relevant cause of METs. Improved diagnostics reveal more synchronous LR  
213 and advanced PTs. More elaborate preparation of sentinel LN detects isolated tumor cells. Occult  
214 METs of all sizes are also present in organs as the distributions of MET-free survival show (Fig.3B).  
215 Late METs were usually initiated shortly before PTs were diagnosed and 10 or more years MET-free  
216 time does not need to be bridged with dormancy. Successful ATs have been shortened to few  
217 months from years ago.<sup>33</sup> This implies that even in large studies no relevant risk by METs could be  
218 demonstrated that would have been initiated by dTCs in the previously longer treatment phase.  
219 Therefore, also an ectopic evolution of TCs in niches should not be a relevant step in the MET-P.<sup>6,34</sup>  
220 Thus, only the risk of MET initiation by TCs of the three sMETs has to be considered (Fig.2A).

### 221 **True local recurrences**

222 True LRs are not considered a source of MET because 39.2% LR after breast conserving surgery did  
223 not result in a higher mortality in the seminal NSABP-B-06 study<sup>11</sup>. The high 4:1 risk found in meta-  
224 analyzes has meanwhile been reduced to the subset of pN+ findings.<sup>35,36</sup> Such a constraint is not  
225 plausible because survival curves show a continuously increasing MET-risk that starts at 0pLN\*  
226 (Fig.2E). This can be also shown by data of the MCR: in the subgroup of non-irradiated patients  
227 where 38.7% of LRs occur without any effect on survival, which reproduces the results of the NSABP-  
228 B-06 study.

### 229 **Positive lymph nodes**

230 Synchronous pLNs are not involved in MET seeding<sup>37</sup>, nor they have yielded convincing evidence of  
231 cascade-like infiltration.<sup>38,39</sup> Long-growing PTs can infiltrate 10 or more LNs. If after a sentinel  
232 extirpation a LN recurrence is diagnosed it is often a singular pLN, which does not infiltrate the  
233 subsequent LN network like PTs. As mentioned above METs are also initiated when no LNs are  
234 involved (Fig.2D). In none of any solid tumor radical LN dissection has resulted in a survival benefit.  
235 This has been demonstrated for BC and more than 10 other tumor types and can also be logically  
236 deduced from Fig.2D.<sup>17,40,41</sup> The more than a century old hypothesis of cascade-like spread cannot be  
237 sustained.<sup>42,43</sup> Survival curves in Fig.2D-E show that the additional MET-risk decreases with each  
238 additional pLN. Therefore, pLNs are dead ends within the MET process.<sup>4</sup>

## 239 **Metastases**

240 METs disseminate TCs with prognostic and predictive relevance.<sup>44</sup> However, cascade-like initiation is  
241 clinically difficult to detect because, due to growth periods, patients would generally not experience  
242 MET initiated by METs. However, there are studies which claim that each sMET can initiate tertiary  
243 METs. Estimates of initiation and growth of METs are usually not considered. In addition, any study  
244 must concede that “we cannot formally exclude an alternative explanation for the observed patterns,  
245 that each of these METs has seeded from an undetected subclone in the PT”.<sup>45</sup> This risk can also be  
246 largely ruled out because multiple MET in different organs and their segments are often genetically  
247 different.<sup>21,46</sup> MET surgery data also points against this argument because, after R0-MET resections,  
248 no new proximal METs limit the successful local resection as in 60% LR (inclusive multifocal LR) of the  
249 PT without irradiation.<sup>47</sup> Taken together, this data supports the hypothesis that LRs, pLNs, and METs  
250 themselves most likely cannot initiate clinically relevant new METs themselves. Therefore, all sMETs  
251 and also 2ndPTs are already prevalent during the primary diagnosis (Fig.1), which are targeted by  
252 primary systemic ATs and/or radiotherapy.

## 253 **Growth duration**

254 The mechanisms of tumor growth remain largely unknown. From the smallest clusters of cells to  
255 angiogenesis in the more advanced disease phase and thereafter, tumor growth varies due to  
256 differential cell divisions inherent to the molecular subtypes and unknown apoptotic rates. In  
257 addition, there are dependencies for extravasation and colonization on the tumor  
258 microenvironment<sup>24</sup>. Nevertheless, growth duration can be estimated based on the initiation period  
259 (Fig.2B), prevalence, PT- and MET-free durations, and can be transformed in volume doubling times  
260 (VDT). The growth of tumor foci can be described by growth trajectories<sup>48</sup> that show the increase in  
261 the cell number over time (Fig.2H). For a cohort, the age distribution of occult METs at the time of  
262 diagnosis and their occurrence during the course of the disease can be elucidated.

## 263 **The growth of PTs**

264 The growth of PTs can lead to METs during the course of the disease. If there are about 1.3% M1 in  
265 pT1a but already 12.3% for pT3 and varying MET-free intervals depending on TD, then the growth of  
266 the PT is also a chronometer for simultaneously growing MET (Fig.2B). There are three approaches to  
267 this process: Estimates from screening data showed a median VDT for women aged 60-69 years  
268 between 10 to 20mm within 143 days.<sup>49</sup> If these growth rates also apply starting from a diameter of  
269 2.5 mm (pT1a) the variability of the VDT with 25%/50% /75% percentiles of 65/143/308 days results  
270 in a growth time between 2.5 to 15 mm (pT1c) in 1.4/3.0/6.5 years (Fig.3A). The 25% percentile at  
271 1.4 years is consistent with the approximately 25% that occur as interval cases in a biennial  
272 screening.<sup>50</sup> The growth time of HR+ preclinical BC, which can be influenced by hormone  
273 replacement therapy, are correspondingly longer. The mean age at diagnosis 60.9 / 61.7 / 64.6 for

274 pT1a-b / pT1c / pT2 also largely reflects PT growth. The great variability of VDT is also apparent for  
275 molecular subtyping.<sup>51</sup> Since sMETs are rare in pT1a-PTs, it follows that all sMETs usually grow faster  
276 than PTs.

277 The second approach is provided by prevention studies. From the first TC, with the above VDTs of  
278 65/143/308 days after 32 VD, a median pT1c-PT would be achieved equivalent to 5.7/12.5/27.0 years  
279 for PT growth. In keeping with this, prevention studies show a continued reduction in incidence even  
280 15 years after the end of a 5 year endocrine chemoprevention.<sup>26,52</sup> Fifteen years of PT growth  
281 corresponds to 171 days of VDs for 32 cell divisions. If the above 143 days are assumed this would  
282 result in a median growth of 12.5 years. That means that at PT diagnosis most of contralateral  
283 2ndPTs for the next 12.5 years are already prevalent. In about 2% of cases synchronous PTs are  
284 detected. At the beginning of the mammography screening recommended for people aged 50 and  
285 over, 4% PTs are not yet detectable but already prevalent, and will occur in the next 12.5 years. The  
286 short-term increase of incidence by postmenopausal estrogen plus progestin therapy and its decline  
287 after weaning can also be explained by the prevalence and growth stimulation of PTs.<sup>53-55</sup> The third  
288 approach is provided by the estimation of MET growth from MET initiation to PT diagnosis.

### 289 **The growth of METs**

290 The growth of METs can be estimated using 4 vertices (Fig.2B): a lower limit for initiation starting at  
291 about 1mm tumor size, the time points of PT and MET diagnosis, as well as tumor-related death. The  
292 growth period for METs consists of the growth up to PT diagnosis and the MET-free time afterwards.  
293 In the special case of primary MET the MET has grown parallel to the PT (Fig.2H). If METs were  
294 initiated at 2.5mm, they would grow a median of 3.0/4.1 years parallel to the pT1c/pT2-PTs and  
295 therefore must have more genomic differences to the PT than late-initiated METs.<sup>56</sup> In tumors of the  
296 size pT2/pT3/pT4 about 4/12/27% are primarily metastasized. In the case of a primary M0 diagnosis  
297 the distribution function of the MET-free time with a follow-up of more than 20 years results in  
298 about 30% METs >10 years and a median of 6 years (Fig.3B).<sup>57</sup>

299 If T-N-M1 cases are also included, the distribution begins with a step corresponding to the proportion  
300 of M1 in all courses of disease with MET (Fig.3B). A perfect regression results with the Gompertz  
301 function  $y(\%) = 98.9 * \exp(-1.82 * \exp(-0.19 * t))$  (-10 - t(years) - 20, MET with HR pos PTs, 1988-97). The  
302 median MET-free times with T-N-M1 result in 2.0/4.8 years for HR neg/pos PTs or together 4.4. years.  
303 The double is 8.8 years or 100 days for 1 VD and a plausible estimate for a median MET growth. The  
304 MET growth varies similar to PT growth. The MET-free time and the time after MET already differ by  
305 a factor of more than 2.4 solely based on the PT HR status (Fig.3B-C). But there is also a great  
306 variability within these subgroups. If the MET-free time is divided into quintiles, then the 5-year  
307 survival after MET is 10%/40% for the outer 20% limit values of approx. <1.5 and > 11 years  
308 (Fig.3D).<sup>58</sup> The longer the MET-free time the more favorable the prognostic factors of the PTs are.

309 This also contradicts a continuous MET initiation from dTCs after R0 removal. METs that would not  
310 be initiated until 5 or 10 years after PT diagnosis would have to grow very fast and most of them  
311 would have to originate from triple negative PTs, which is not observed. Growth rate variability  
312 reflects the distribution of event-free times, which are positively skewed with a long upper tail for  
313 METs that occur without dormancy phases after 15 years or more. Despite the increase in MET  
314 frequency with TD, MET is an autonomous process within molecular subgroups. Larger PTs do not  
315 initiate more aggressive METs. According to this principle METs initiated early or later on grow  
316 comparably fast (Figs.2H, 3C), therefore MET-competence of TCs is a qualitative not a quantitative  
317 characteristic. METs can acquire additional mutations (Fig.1)<sup>3</sup> and become a moving target for  
318 precision oncology, which does not seem to affect growth rates.

### 319 **The growth of LRs**

320 The growth of LRs can be read from two time durations: Late initiations of true LR occur immediately  
321 before PT removal and are likely to have the longest LR-free times. This growth period of true LRs can  
322 be read from the breast conserving surgery studies with and without radiation<sup>35</sup> and is about 6 years  
323 (Fig.3E) because thereafter the slope of the cumulative incidence of LRs is the same in both groups.  
324 The earliest initiations of true LRs results in 18% multifocal findings and without them the median LR-  
325 free time is approximately 2.5 years and independent of follow-up (Fig.3E), while median ipsilateral  
326 2ndPT-free time increases to half the follow-up time due to continuous initiation of PTs (Fig.2H).<sup>59,60</sup>  
327 Six years of growth results in a VDT of about 68 days and 32 VDs, almost 2.1 as fast as that of the PTs.

### 328 **The growth of pLNs**

329 The growth of pLNs cannot be easily estimated because valid vertices in the form of pLN-free  
330 intervals are lacking. In addition, LN dissections are frequent in pLNs and LN recurrences are rare.  
331 According to data of the MCR in 100 patients with pT1b-BC (7.5 mm), 13% pN+ and a total of about  
332 36 pLNs are to be expected. If PTs reach a diameter of 15mm after about 14 months, 42 more LNs  
333 are infiltrated, in total 25% pLNs. In today's serial sentinel preparation, small PTs have about 12%  
334 macro-METs and almost as many isolated TCs and micro-METs.<sup>61,62</sup> If the 12% newly infiltrated LNs  
335 had a size of 0.2mm at 7.5mm (border between ITC and micro-MET) and then grew to a size of 2mm,  
336 this results in a VDT of 43 days, 3.3 times that of PTs.<sup>39</sup>

### 337 **MET-free and post-MET survival**

338 The survival of a MET-related death is composed of three periods of MET growth (Fig. 2B), the time  
339 to PT diagnosis, the MET-free time, and the post-MET survival. If PTs from 1mm TD can initiate MET,  
340 then this will become even more likely with an increasing size of the PT. The longer a PT  
341 disseminates, i.e. the larger the PT, the longer the occult MET growth and the shorter the MET-free  
342 survival time. This also applies to pLNs. Of all METs 35% occur with 0pLNs. The MET-risk increases

343 when micro-METs are already detectable in LNs and it doubles when the first LN is positive (Fig.  
344 2D).<sup>39,61,62</sup> If more LNs become positive these occult METs continue to grow, the MET-free intervals  
345 become increasingly shorter, with more than 15 pLNs PT and MET are diagnosed together in 20% of  
346 cases. The number of pLNs is the most important clinical prognostic factor, it may even be  
347 considered a chronometer for METs but not a cause thereof.<sup>39,40</sup> Nevertheless, extended LN  
348 dissections for MET-risk reduction unfortunately are still found in the literature.

349 True LRs are caused by disseminating PTs, which can also initiate METs in parallel to LNs and organs.  
350 As in the NSABP-B06 trial there is no MET-risk in MCR data. The group without radiation has an  
351 overall less favorable prognosis (Fig. 2F). In addition, the growth times of the MET do not match the  
352 4:1 survival effect<sup>35</sup> that should occur without irradiation due to the not avoided LRs and their  
353 caused METs. The lack of MET-risk is also supported for synchronous true LR, i.e. multifocal findings,  
354 for which no increased MET-risk could be detected.<sup>63,64</sup> Progression data in Fig. 3B-D are easier to  
355 interpret if the progression-free times are not considered from diagnosis but from the initiation of  
356 the progressions, which occur about twice the median time before the progression detection  
357 (Fig.3D). Differences in growth are clearly recognizable in the long follow-up by the median of the  
358 MET-free periods of the subgroups.

359 The diagnosis of MET has no influence on MET growth. For this reason, all courses of the disease are  
360 synchronized with this point in time and the temporary post-MET survival reveals the influence of the  
361 various growth factors. Median post-MET survival varies e.g. at Ki67 between 0.7-3 years and is  
362 linearly correlated with the MET-free survival (Fig.3C). Since growth also varies by a factor of 10 or  
363 more with a qualitative characteristic such as HR status, there must be a quantitative molecular  
364 biomarker for the growth rate that correlates higher than the combination HR and Ki67.

365 A rare MET in pT1b-c is usually not a particularly aggressive tumor. Rather, the correlations show that  
366 larger PTs that later initiate MET, grow faster and pass on these growth characteristics to the MET.  
367 Therefore, the duration of the MET-free time is an important prognostic factor for survival after MET  
368 (Fig.3E). However, this variability is limited by the extent of the MET and the MET localization  
369 because e.g. median survival after bone and CNS-MET differ by the factor 3.1.<sup>65</sup>

### 370 **Hypotheses about tumor growth and the MET process**

371 Available evidence from well-known data about PT findings and the course of disease provide a  
372 plethora of facts and hypotheses about initiating, growth and effects of today's successful neo- and  
373 ATs. Neither initiation of METs by secondary foci nor a long-term delay through dormancy has been  
374 demonstrated. This could be summarized in an ***immediate MET initiation principle by the primary***  
375 ***tumor, e.g. without delay by dormant TCs.***

376 Growing PTs continuously initiate life-threatening METs. Derived from tumor-specific mortality, the  
377 cumulative incidence of MET as a function of TD is also nonlinear and follows a Gompertz function.  
378 This is a **growth dependent metastasis principle**: With every millimeter of a growing PT the  
379 proportion of METs increases, with early and late MET being less frequent compared to the  
380 maximum at the inflection point of the Gompertz function at 21mm. This random process leads to a  
381 variability in the age of the MET at diagnosis and the MET-free time, which together give a mean  
382 duration for MET growth of about 8,8 years (Fig.2H).

383 Growth rates of PTs and their METs can each differ by a factor of 10 and more with a long upper tail  
384 (Fig.3A). Despite the great variability and molecular heterogeneity, the dissemination of TCs and  
385 initiation of pLNs and METs, depending on TD, are likely comparable. The processes only take place  
386 with varying speeds which can be considered a relativity principle, in other words **a time lapse**  
387 **principle**. Therefore, the properties of 25% interval PTs are comparable to populations without  
388 biennial screening despite their rapid growth<sup>50</sup>, or early advanced PTs are not predominantly triple  
389 negative PTs.

390 Triple negative or luminal A-PTs usually do not initiate contrary METs. That is, the relationship of the  
391 growth rates of PTs and their METs varies only slightly (Fig.3F). The relationship must be greater than  
392 1 because there are M1-PTs and it cannot be 10 or more because then there would be mostly M1-  
393 PTs. The estimate of about 8.8 years of growth for MET and 12.5 years for PT results in the factor 1.4.  
394 This growth relation can be seen as a relativity principle of the MET process, **a constant MET-PT**  
395 **growth relation principle**.

396 Dissemination, acquisition of MET-competence, MET initiation, and growth rates are likely to be  
397 independent principles. HR-status causes different growth rates and is the first target for treatment  
398 but not a driver of the MET-P. The comparable tumor-specific long-term survival supports these  
399 principles and is a challenge for gene expression tests (Fig.3G).<sup>66</sup>

#### 400 **Effect of adjuvant and neoadjuvant treatments**

401 The principles of MET-P can explain successes, limitations, and opportunities of ATs and conversely  
402 successful ATs can confirm MET-P principles. All secondary foci are already prevalent at primary  
403 therapy because LR, pLNs, and METs cannot be initiated after removal of the 1stPT. There are three  
404 questions that remain about successful ATs: 1. From and up to what size are METs eradicated? 2.  
405 How many METs are eradicated? 3. How long do ATs have to last? The same questions also apply to  
406 occult contralateral and ipsilateral 2ndPTs, the latter due to the current practice of predominantly  
407 breast conserving surgery.

#### 408 **Eradication of primary tumors**

409 Complete pathological remissions of over 50% can be achieved with neo-ATs in a few weeks.<sup>67-69</sup>  
410 Endocrine therapies achieve a less complete remission, but downsizing and prolonged localized  
411 control of the PT are possible.<sup>70-73</sup> The lower efficacy of endocrine neo-ATs depends on the size of  
412 PTs, because the reduction of the incidence by chemoprevention starts after a short delay.<sup>26,74</sup> The  
413 delay is less than 3 VDs and can be interpreted as a lead time effect via the inclusion criteria of a  
414 negative mammography exam. Thus, prevention also works in the short term, especially under  
415 aromatase inhibitor treatment.<sup>75</sup> Since further 1stPTs are initiated during the 5 years in the  
416 prevention studies, the eradication of these smallest clusters becomes apparent 15 years later. This  
417 means that the prevention successfully eradicates about 50% PTs of all sizes up to a threshold of  
418 almost detectable 1stPTs. This is exactly how endocrine ATs act on 2ndPTs, and this has been  
419 confirmed many times on the contralateral 2ndPTs.<sup>76</sup> In both situations 1st and 2ndPTs of the next  
420 12.5 years are prevalent at the beginning of prevention. There is no rationale for 5 years of  
421 prevention. On the contrary, the incidence curves suggest that shorter chemopreventions are  
422 possible.

#### 423 **Eradication of metastases**

424 Overt METs have not been eradicable until today. This also applies to nearly detectable MET,  
425 because in clinical trials with (neo-) ATs the survival curves of MET-free time do not separate in the  
426 first months.<sup>77-79</sup> Thus, there is a size-dependent upper threshold for effectiveness comparable to  
427 chemoprevention. A lower limit is not recognizable from our historical data because successful ATs  
428 have achieved a uniform eradication of even the smallest METs (Fig.3H).

429 This is shown by the distribution of the number of pLNs: the fraction with 0pLN\* and 1-3 pLNs is  
430 largely independent of the TD (Fig. 2E), but the mortality increases with each additional pLN (Fig.2D).  
431 In these subgroups, there are a similar number of small METs which can be destroyed by ATs. This  
432 explains the more than 10% improvement in survival seen in the past decades, independent of the PT  
433 size.<sup>58,80</sup> With a favorable prognosis (0pLN, pT1) the relative 5-year survival now reaches 99%  
434 (Fig:2C,D,G).<sup>25</sup>

435 Alternatives such as the selective eradication of early-initiated MET with few mutations or late-onset  
436 MET due to smaller foci are not recognizable (Fig.3H). However, the already mentioned successful  
437 ATs of the past few decades provide a selective eradication of METs: Nowadays, METs in bone and  
438 lung are about 50% and 30% less common, whereas there is no evidence of clinically relevant  
439 eradication in the liver and CNS METs until now. Such successful ATs produce a paradoxical effect. If  
440 the early bone METs become less frequent and the progression begins with the later CNS METs, then  
441 MET-free survival becomes longer and post-progression survival becomes shorter.<sup>58,81</sup> In contrast, the

442 MET pattern in T-N-M1 (at diagnosis) has not changed in the last decades because it is untreated and  
443 mirrors the biology of BC.<sup>65</sup> A rationale for the duration of the therapies is not known.

444 The process is also explained when the effects of delayed treatments are considered.<sup>82</sup> If surgery is  
445 postponed by a few weeks, further METs and pLNs are initiated with every additional millimeter of  
446 TD. This is the contrary of the logic of screening to shorten the duration of the dissemination of the  
447 PTs and thereby prevent METs (Fig. 2B-C). If ATs are started with a delay, there is initially the same  
448 effect as if they were started immediately.<sup>83</sup> However, as all prevalent METs continued to grow  
449 during the delay, there are fewer eradicable METs and some have exceeded the eradicability  
450 threshold (Fig.2H).<sup>83,84</sup> That also suggests the effectiveness of short treatment durations and justifies  
451 the AT question of “how short is short enough”.

#### 452 ***Eradication of LR and pLNs***

453 *Control* of true LR is nearly perfect through irradiation. Radiation therapies even made breast  
454 conserving surgery possible due to its exceptional efficacy in faster growing LRs compared to PTs  
455 which are also prevalent in the form of ipsilateral 2ndPTs (Fig.3E).<sup>11</sup> Therefore, ATs may improve local  
456 control of multifocal and multicenter LRs, the different origins of which should be shown by their  
457 clonality.<sup>85</sup>

458 *Regional control of pLNs* is also achieved with today's surgical and neo-ATs making a LN relapse in  
459 <5% of cases during a time span of 15 years a rare event. Survival is optimal if no residual tumor  
460 remains after neo-AT primary and in the LNs.<sup>67,69</sup> Thus, ATs also contribute to regional control  
461 because in the absence of an axillary dissection they act as neo-ATs on not removed LNs with isolated  
462 TCs and micro-METs.<sup>40,86</sup>

#### 463 **Hypotheses about neo- and adjuvant treatments**

464 Treatment cohorts of MCR and clinical studies suggest five most likely principles of treatment: First,  
465 chemopreventions of 1stPT and 2ndPTs show that about 50% can be eradicated, regardless of  
466 whether the PT develops during the therapy, is already prevalent and very small or almost  
467 detectable. Secondly, with neo-AT a complete pathological remission is possible in 50%. Thirdly,  
468 successful neo- and adjuvant therapies can also eradicate METs of all sizes until just before  
469 detectability. In addition, an organ-specific effectiveness must be considered. Forthly, the eradication  
470 of PTs and METs is achieved quickly, which can be derived from opening of survival curves and is  
471 supported by successful shortening or unsuccessful extension of the treatment periods. Fifthly, this  
472 data suggests the hypothesis that the rapid efficacy makes intrinsic resistance in PTs and METs more  
473 likely than a therapy-induced resistance.<sup>87</sup>

#### 474 **Discussion of possible improvements**

475 These principles of today's treatments are evident. However, they also illustrate the limits of  
476 treatment and an inadequate quantification of treatment-associated factors. These circumstances  
477 should motivate innovative steps in the optimization of treatment for PTs and METs. The first  
478 question concerns the required duration of successful treatments. If there is no rationale for the  
479 duration of a treatment regimen there will be both an under- and overtreatment. Longer treatment  
480 periods are more likely to be tested.<sup>88</sup> Optimization studies are problematic in terms of research  
481 ethics and not scientifically attractive. But there are also trials with shorter duration of ATs, e.g. also  
482 in colorectal cancers.<sup>89,90</sup> Real world data could help to fill this gap in knowledge. Considering  
483 personalized medicine targets in BC are already the standard of care. If PT growth can vary by a  
484 factor of 10 or more associating the duration of treatment to a biomarker for cell division could be a  
485 step to a more personalized treatment. A specific example is extended endocrine AT.<sup>91-93</sup> Although  
486 improved outcome is evident and also logical (Fig.2H), there is no rationale for long-term therapies.  
487 Therefore, the interpretation of the trial is questionable and the applicable principle from our data  
488 suggest a possible 70% reduction of overtreatment through intermittent therapies.<sup>94</sup> Further  
489 implications concern LN dissections and after-care. Despite many studies, pLNs are not a cause of  
490 MET and therefore extended LN dissections cannot be justified and the efficiency of expensive  
491 diagnostics in aftercare has not been shown, which can actually be explained with the principles  
492 presented.

493 Second, the long periods of growth lead to the issue of which occult foci are eradicated. MET-free  
494 times show that M1 or almost M1 are an upper limit of effectiveness. This also applies to  
495 chemoprevention, in which new PTs are also eradicated during therapy. This results in a de-  
496 escalation principle for ATs in the sense of "how short is short enough" instead of an overtreatment  
497 impulse with "how long is long enough".<sup>95,96</sup> Chemoprevention requires intermittent treatment  
498 because new PTs are created throughout a lifetime.

499 Third, the rapid and selective efficacy of therapies requires focus. At MET, efficacy is first coupled to  
500 the microenvironment. MET in bone and lung are reduced by successful ATs, CNS and liver are  
501 inaccessible and pharmacokinetic causes and molecular mechanism are discussed.<sup>97</sup> From prevention  
502 trials<sup>26</sup> we know that about 50% of HR+ PTs of all sizes may become resistant. The rapid eradication  
503 of PTs<sup>67,79</sup> and METs<sup>98</sup> within 1-2 VDs suggests that a non-responsive tumor is more of a consequence  
504 of intrinsic resistance mechanisms than of acquired ones.<sup>99,100</sup> This is also supported by the fact that  
505 there are many gene expression signatures that are predictive of poor outcome and whose genes  
506 influence estrogen receptors, apoptosis, or MET.<sup>101</sup> Meticulous observations, laboratory and  
507 mathematical models can further clarify the statements and shorten the path to innovation,  
508 especially because the described relationships are highly likely.

509 **Conclusions**

510 Clinical trials and real-world data with lifelong follow-up and progression-free and the post-  
511 progression survival elucidate dissemination of TCs, initiation and growth of sMET as well as PTs.  
512 Four principles describe tumor growth and the MET-P and form a framework for scientific terms,  
513 molecular hypotheses, and treatments. Dormancy and stepwise MET initiations by sMETs are not  
514 supported by data. Also, principles about neo- and ATs can be derived from data about successes and  
515 limits of preventive, diagnostic and therapeutic interventions. Tumor growth and successful changed  
516 MET patterns question the duration of preventive and ATs.

517 Primarily, real world cancer registry data should clarify how findings, treatments, or MET pattern  
518 change and which medical advances have a relevant impact on a population. With quantitative  
519 models<sup>102</sup> and comparative effectiveness analyzes<sup>103,104</sup> hypotheses about tumor growth and  
520 therapies can be derived and validated from the data. Feedback from this data analyzes can support  
521 delivery of care and improve its quality, especially when many outcome parameters are compared.  
522 Impulses for health care-relevant translational research can be given. Linking cancer registry data to  
523 biomaterial and sequencing data could accelerate interdisciplinary knowledge acquisition for  
524 innovation. Such expansions of the systematic use of available data can become a vast source of  
525 knowledge.

526 **Appendices:**

527 **Disclosure:** The authors have declared no conflicts of interest.

528

529 **Acknowledgment**


530 We thank the clinics, doctors and teams of the general practitioners, the departments of pathology  
531 and radiation oncology for the systematic transfer of their findings and treatments. In particular, we  
532 would like to thank the staff of the Munich Cancer Registry for their meticulous and systematic  
533 recording and maintenance of the data. The Project Group Breast Cancer of our Comprehensive  
534 Cancer Centers has regularly discussed questions and results with the MCR. Thank you very much.

535

536 **Figures**

537 **Figure 1 Initiation and growth of a PT and secondary foci**


538  
 539 Growing PTs can initiate LR, pLNs and METs with different gene signature. They can be diagnosed  
 540 synchronously with PTs (filled symbols), remain occult, will be eradicated by ATs or occur in the  
 541 course of disease. (The article and this figure were inspired by LR Yates et al (2017).<sup>3</sup>)  
 542



543

544 **Figure 2: 2A – 2H combined**

545



546


547

548 **Legends Figure 2**

549 (A) Tumor cell dissemination and initiation of LRs, pLNs, METs. (B) Tumor size dependent MET and  
550 pLN initiation and survival. I: METs can be initiated until the removal of a PT. II: PTs will initiate up to  
551 pT1c about 10% METs, 1.5% are already T-N-M1. III: During growth up to pT2, 4.5% become T-N-M1,  
552 25% METs and 20.3% pLNs are additionally initiated which can be avoided by early detection at pT1.  
553 Equal rapid MET growth is outlined. Because of successful ATs, the percentages depend on the  
554 reference period and can therefore vary. (C) Relative\* survival depending on tumor diameter for T-N-  
555 M0 PTs. (D) Relative\* survival depending on the number of pLNs. The arrows are the same length.  
556 The length corresponds to the mortality of 20% in 0pLNs after 20 years. The arrows show the  
557 decreasing risk of the increasing number of pLNs. (E) Lymph node infiltration. Distribution of the  
558 number of pLNs in dependence on tumor diameter (n=30,170). Cumulative observed data (dotted  
559 lines) and fitted Gompertz functions (Gf) (solid lines) show for each TD the percentages with >npLNs.  
560 The dotted black line estimates the proportion of patients (0pLN\*) with METs initiated during 0pLN-  
561 status. The length corresponds to the MET-risk of 0pLNs and 1pLN in Fig. 2D. The black line is the  
562 fitted Gf for the observed tumor specific 15-year mortality (diamonds) depending on TD. The stacked  
563 barplot visualizes the distribution of pLNs at 22.5mm TD. (F) Overall survival for patients with pT1-2  
564 PTs, breast conserving surgery and irradiation. The blue dotted and dashed subgroups are samples  
565 with the same distribution of age, pT and LNs as the subgroup without radiation (brown curve),  
566 which is further divided according to the occurrence of LRs. (G) Relative\* survival for pT1c and pT2  
567 PTs and 4 time periods from 1978. The improvement after 15 years is about 10% absolute in both  
568 subgroups. (H) Growth trajectories for MET and 2ndPTs. Each trajectory describes the number of TCs  
569 (log scale) as a function of a median growth time (8 MET or 12 PT years) relative to the PT. The age of  
570 a MET or 2ndPT at the time of diagnosis of the 1stPT indicate the age scales. The sum of age and  
571 event-free survival is on average constant. Blue trajectories represent synchronous events, black  
572 ones for 2nPTs, which are initiated after PT diagnosis. The age distributions of METs are snapshots at  
573 the time of PT diagnosis and a delayed time afterwards. Since no new METs are initiated, there are  
574 no small METs for delayed ATs and the larger ones have already been discovered.  
575 \*The relative survival is an estimate for tumor-specific survival and is calculated by dividing the overall survival  
576 after diagnosis by the survival observed in the general population with comparable age distribution.

577 **Figure 3: 3A – 3H combined**

578



579


580 **Legends Figure 3**

581 **(A)** Volume doubling and tumor growth. Growth durations of PTs from 2.5mm depending on  
582 estimates of the 25% / 50% / 75% percentiles VDTs according to H. Weedon-Fekjaer 49 The variability  
583 is illustrated by the growth times from 2.5 mm up to pT1c or pT2-PT. **(B)** Hormone receptor  
584 dependent MET-free survival. Distribution functions of the MET-free times for T-N-M0 and HR  
585 positive (red) and HR negative (blue) PTs from the time periods 1988-97 and 1998-2007. Because of  
586 the observation period of 20 years the distributions from 1998-2007 reach almost 100% at 20 years.  
587 About 30% of the MET appear after 10 years. The dashed lines also show the fraction of T-N-M1 for  
588 1988-97 **(C)** Cumulative incidence of METs and survival after MET depending on KI67. The median  
589 survival at T-N-M0 in the event of tumor-related death for the two outer subgroups is approximately  
590 3.1 and 1.5 years. The post MET survival curves are covered at 22%. **(D)** Cumulative incidence of LRs  
591 after breast conserving surgery with and without irradiation. Black dotted lines are parallels and  
592 show that late LRs increases in both groups comparable to the incidence of contralateral 2ndPT. The  
593 dotted blue curve is similar to those for LRs without irradiation and is the fictive initiation of true LR  
594 after forwarding the twofold LR-free time of about 26 months. **(E)** Overall survival from MET of HR+  
595 PTs as a function of MET-free time. PTs are diagnosed between 1988-2006 with > 20 years follow-up  
596 and n=8,127 METs observed. The differences of PTs of the 1st and 5th Quintile (<1.5, ≥11 ys) are  
597 12.4/36.9% for 5 years survival, 23.9%/45.7% for pT1 and 18.3 / 42.4% for pN0. **(F)** MET-PT growth  
598 relation principle. Relation of tumor growth of PTs and METs (pT1,pT2), MET-free survival and post  
599 MET-survival (red) at different growth rates.<sup>49</sup> **(G)** Relative survival of HR positive and negative PTs.  
600 **(H)** Time trend of bone MET-free survival. Cumulative incidence of bone METs as a function of 4 time  
601 periods since 1978. (Kaplan-Meier method without concurrent risks) The black lines sketch fictitious  
602 selective eradication of early (dashed) or late (dotted) initiated METs alternative to green line.

603 **Supplement: 16 Figures 2A-3H shown individually with a higher resolution**

604 **Figure 2A** Tumor cell dissemination and initiation of LRs, pLNs, METs

605



606

607 **Figure 2B** Tumor size dependent MET and pLN initiation and survival


608 **I:** METs can be initiated until the removal of a PT. **II:** PTs will initiate up to pT1c about 10% METs,

609 1.5% are already T-N-M1. **III:** During growth up to pT2, 4.5% become T-N-M1, 25% METs and 20.3%

610 pLNs are additionally initiated which can be avoided by early detection at pT1. Equal rapid MET

611 growth is outlined. Because of successful ATs, the percentages depend on the reference period and

612 can therefore vary.




613

614 **Figure 2C** Tumor diameter

615 Relative\* survival depending on tumor diameter for T-N-M0 PTs.


616 \*The relative survival is an estimate for tumor-specific survival and is calculated by dividing the overall survival  
617 after diagnosis by the survival observed in the general population with comparable age distribution.



618

619 **Figure 2D** positive LNs


620 Relative survival depending on the number of pLNs. The arrows are the same length. The length  
621 corresponds to the mortality of 20% in 0pLNs after 20 years. The arrows show the decreasing risk of  
622 the increasing number of pLNs.



623

624 **Figure 2E** Lymph node infiltration


625 Distribution of the number of pLNs in dependence on tumor diameter (n=30,170). Cumulative  
 626 observed data (dotted lines) and fitted Gompertz functions (Gf) (solid lines) show for each TD the  
 627 percentages with >npLNs. The dotted black line estimates the proportion of patients (OpLN\*) with  
 628 METs initiated during OpLN-status. The length corresponds to the MET-risk of OpLNs and 1pLN in Fig.  
 629 2D. The black line is the fitted Gf for the observed tumor specific 15-year mortality (diamonds)  
 630 depending on TD. The stacked barplot visualizes the distribution of pLNs at 22.5mm TD.  
 631




632

633 **Figure 2F** Overall survival after breast conserving surgery and irradiation


634 Overall survival for patients with pT1-2 PTs, breast conserving surgery and irradiation. The blue  
 635 dotted and dashed subgroups are samples with the same distribution of age, pT and LNs as the  
 636 subgroup without radiation (brown curve), which is further divided according to the occurrence of  
 637 LRs.



638 **Figure 2G** Trend: relative Survival depending on pT1-2  
 639 Relative survival for pT1c and pT2 PTs and 4 time periods from 1978. The improvement after 15 years  
 640 is about 10% absolute in both subgroups




641 **Figure 2H** Growth trajectories  
 642 Growth trajectories for MET and 2ndPTs. Each trajectory describes the number of TCs (log scale) as a  
 643 function of a median growth time (8 MET or 12 PT years) relative to the PT. The age of a MET or  
 644 2ndPT at the time of diagnosis of the 1stPT indicate the age scales. The sum of age and event-free  
 645 survival is on average constant. Blue trajectories represent synchronous events, black ones for 2ndPTs,  
 646 which are initiated after PT diagnosis. The age distributions of METs are snapshots at the time of PT  
 647 diagnosis and a delayed time afterwards. Since no new METs are initiated, there are no small METs  
 648 for delayed ATs and the larger ones have already been discovered.



650 **Figure 3A** Volume doubling and tumor growth


651 Growth durations of PTs from 2.5mm depending on estimates of the 25% / 50% / 75% percentiles  
 652 VDTs according to H. Weedon-Fekjaer<sup>49</sup> The variability is illustrated by the growth times from 2.5  
 653 mm up to pT1c or pT2-PT.



654


655 **Figure 3B** Hormone receptor dependent MET-free survival

656 Distribution functions of the MET-free times for T-N-M0 and HR positive (red) and HR negative (blue)  
 657 PTs from the time periods 1988-97 and 1998-2007. Because of the observation period of 20 years the  
 658 distributions from 1998-2007 reach almost 100% at 20 years. About 30% of the MET appear after 10  
 659 years. The dashed lines also show the fraction of T-N-M1 for 1988-97.




660

661 **Figure 3C** Cumulative incidence of METs and survival after MET depending on Ki67.  
 662 The median survival at T-N-M0 in the event of tumor-related death for the two outer subgroups is  
 663 approximately 3.1 and 1.5 years. The post MET survival curves are covered at 22%.




664  
 665 **Figure 3D** Cumulative incidence of LRs after breast conserving surgery with and without irradiation.  
 666 Black dotted lines are parallels and show that late LRs increases in both groups comparable to the  
 667 incidence of contralateral 2ndPT. The dotted blue curve is similar to those for LRs without irradiation  
 668 and is the fictive initiation of true LR after forwarding the twofold LR-free time of about 26 months.




669

670 **Figure 3E** Overall survival from MET of HR+ PTs as a function of MET-free time  
 671 PTs are diagnosed between 1988-2006 with > 20 years follow-up and n=8,127 METs observed. The  
 672 differences of PTs of the 1st and 5th Quintile (<1.5, ≥11 ys) are 12.4/36.9% for 5 years survival,  
 673 23.9%/45.7% for pT1 and 18.3 / 42.4% for pN0.




674

675 **Figure 3F** MET-PT growth relation principle  
 676 Relation of tumor growth of PTs and METs (pT1,pT2), MET-free survival and post MET-survival (red)  
 677 at different growth rates <sup>49</sup>



678


679 **Figure 3G** Relative survival of HR positive and negative PTs.



680

681 **Figure 3H** Time trend of bone-MET-free survival

682 Cumulative incidence of bone METs as a function of 4 time periods since 1978. (Kaplan-Meier  
 683 method without concurrent risks) The black lines sketch fictitious selective eradication of early  
 684 (dashed) or late (dotted) initiated METs alternative to green line.



685

686 **References:**

- 687 1. Valastyan S, Weinberg RA: Tumor metastasis: molecular insights and evolving  
688 paradigms. *Cell* 147:275-92, 2011
- 689 2. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. *Cell* 144:646-74,  
690 2011
- 691 3. Yates LR, Knappskog S, Wedge D, et al: Genomic Evolution of Breast Cancer  
692 Metastasis and Relapse. *Cancer Cell* 32:169-184.e7, 2017
- 693 4. Lambert AW, Pattabiraman DR, Weinberg RA: Emerging Biological Principles of  
694 Metastasis. *Cell* 168:670-691, 2017
- 695 5. Peinado H, Zhang H, Matei IR, et al: Pre-metastatic niches: organ-specific homes for  
696 metastases. *Nat Rev Cancer* 17:302-317, 2017
- 697 6. Husemann Y, Geigl JB, Schubert F, et al: Systemic spread is an early step in breast  
698 cancer. *Cancer Cell* 13:58-68, 2008
- 699 7. Narod SA, Sopik V: Is invasion a necessary step for metastases in breast cancer?  
700 *Breast Cancer Res Treat* 169:9-23, 2018
- 701 8. Butler TP, Gullino PM: Quantitation of cell shedding into efferent blood of mammary  
702 adenocarcinoma. *Cancer Res* 35:512-6, 1975
- 703 9. Menyailo ME, Tretyakova MS, Denisov EV: Heterogeneity of Circulating Tumor Cells  
704 in Breast Cancer: Identifying Metastatic Seeds. *Int J Mol Sci* 21, 2020
- 705 10. Cresswell GD, Nichol D, Spiteri I, et al: Mapping the breast cancer metastatic cascade  
706 onto ctDNA using genetic and epigenetic clonal tracking. *Nat Commun* 11, 2020
- 707 11. Fisher B, Anderson S, Bryant J, et al: Twenty-year follow-up of a randomized trial  
708 comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of  
709 invasive breast cancer. *N Engl J Med* 347:1233-41, 2002
- 710 12. Panet-Raymond V, Truong PT, McDonald RE, et al: True recurrence versus new  
711 primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy. *Int J*  
712 *Radiat Oncol Biol Phys* 81:409-17, 2011
- 713 13. Whipp E, Beresford M, Sawyer E, et al: True local recurrence rate in the conserved  
714 breast after magnetic resonance imaging-targeted radiotherapy. *Int J Radiat Oncol Biol Phys* 76:984-  
715 90, 2010
- 716 14. Comen E, Norton L: Self-seeding in cancer. *Recent Results Cancer Res* 195:13-23,  
717 2012
- 718 15. Kim MY, Oskarsson T, Acharyya S, et al: Tumor self-seeding by circulating cancer cells.  
719 *Cell* 139:1315-26, 2009
- 720 16. Brierley JD, Gospodarowicz MK, Wittekind C, et al: The TNM Classification of  
721 Malignant Tumours 8th ed. Wiley & Sons, 2016
- 722 17. Engel J, Weichert W, Jung A, et al: Lymph node infiltration, parallel metastasis and  
723 treatment success in breast cancer. *Breast* 48:1-6, 2019
- 724 18. Mamounas EP, Kuehn T, Rutgers EJT, et al: Current approach of the axilla in patients  
725 with early-stage breast cancer. *Lancet*, 2017
- 726 19. Munich Cancer Registry: <http://www.tumorregister-muenchen.de/en/> (accessed  
727 March 20, 2020).
- 728 20. Turajlic S, Swanton C: Metastasis as an evolutionary process. *Science* 352:169-75,  
729 2016
- 730 21. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic  
731 evolution of pancreatic cancer. *Nature* 467:1114-7, 2010
- 732 22. Zhang XH, Jin X, Malladi S, et al: Selection of bone metastasis seeds by mesenchymal  
733 signals in the primary tumor stroma. *Cell* 154:1060-73, 2013
- 734 23. Bos PD, Zhang XH, Nadal C, et al: Genes that mediate breast cancer metastasis to the  
735 brain. *Nature* 459:1005-9, 2009
- 736 24. Weiss L: Comments on hematogenous metastatic patterns in humans as revealed by  
737 autopsy. *Clin Exp Metastasis* 10:191-9, 1992
- 738 25. Noone A, Howlander N, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2015  
739 National Cancer Institute. Bethesda, MD; <http://seer.cancer.gov/> (accessed March 20, 2020).

- 740 26. Cuzick J, Sestak I, Cawthorn S, et al: Tamoxifen for prevention of breast cancer:  
741 extended long-term follow-up of the IBIS-I breast cancer prevention trial. *Lancet Oncol* 16:67-75,  
742 2015
- 743 27. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of  
744 developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst*  
745 81:1879-86, 1989
- 746 28. Chaudary MA, Millis RR, Hoskins EO, et al: Bilateral primary breast cancer: a  
747 prospective study of disease incidence. *Br J Surg* 71:711-4, 1984
- 748 29. Aguirre-Ghiso JA, Bragado P, Sosa MS: Metastasis Awakening: Targeting dormant  
749 cancer. *Nat Med* 19:276-7, 2013
- 750 30. Oskarsson T, Batlle E, Massague J: Metastatic stem cells: sources, niches, and vital  
751 pathways. *Cell Stem Cell* 14:306-21, 2014
- 752 31. Meng S, Tripathy D, Frenkel EP, et al: Circulating tumor cells in patients with breast  
753 cancer dormancy. *Clin Cancer Res* 10:8152-62, 2004
- 754 32. Janni W, Vogl FD, Wiedswang G, et al: Persistence of disseminated tumor cells in the  
755 bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled  
756 analysis. *Clin Cancer Res* 17:2967-76, 2011
- 757 33. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast  
758 cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000  
759 recurrences and 24,000 deaths among 75,000 women. *Early Breast Cancer Trialists' Collaborative*  
760 *Group. Lancet* 339:71-85, 1992
- 761 34. Hunter KW, Amin R, Deasy S, et al: Genetic insights into the morass of metastatic  
762 heterogeneity. *Nat Rev Cancer* 18:211-223, 2018
- 763 35. Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and of  
764 differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:  
765 an overview of the randomised trials. *Lancet* 366:2087-106, 2005
- 766 36. Early Breast Cancer Trialists' Collaborative Group: Effect of radiotherapy after breast-  
767 conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of  
768 individual patient data for 10 801 women in 17 randomised trials. *Lancet* 378:1707-16, 2011
- 769 37. Ullah I, Karthik GM, Alkodsí A, et al: Evolutionary history of metastatic breast cancer  
770 reveals minimal seeding from axillary lymph nodes. *J Clin Invest* 128:1355-1370, 2018
- 771 38. Cady B: Lymph node metastases. Indicators, but not governors of survival. *Arch Surg*  
772 119:1067-72, 1984
- 773 39. Engel J, Emeny RT, Holzel D: Positive lymph nodes do not metastasize. *Cancer*  
774 *Metastasis Rev* 31:235-246, 2012
- 775 40. Giuliano AE, Ballman KV, McCall L, et al: Effect of Axillary Dissection vs No Axillary  
776 Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node  
777 Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. *Jama* 318:918-926, 2017
- 778 41. Engel J, Lebeau A, Sauer H, et al: Are we wasting our time with the sentinel  
779 technique? Fifteen reasons to stop axilla dissection. *Breast* 15:452-5, 2006
- 780 42. Halsted W: The results of operations for the cure of the cancer of the breast  
781 performed at the Johns Hopkins Hospital from June 1889 to January 1894. *Arch Surgery* 20:497, 1894
- 782 43. Crile G: Excision of cancer of the head and neck. *JAMA* 47:1780-1786, 1906
- 783 44. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression,  
784 and survival in metastatic breast cancer. *N Engl J Med* 351:781-91, 2004
- 785 45. Gundem G, Van Loo P, Kremeyer B, et al: The evolutionary history of lethal  
786 metastatic prostate cancer. *Nature* 520:353-357, 2015
- 787 46. Ramaswamy S, Ross KN, Lander ES, et al: A molecular signature of metastasis in  
788 primary solid tumors. *Nat Genet* 33:49-54, 2003
- 789 47. Hölzel D, Eckel R, Emeny R, et al: Distant metastases do not metastasize. *Cancer*  
790 *Metastasis Rev* 29:737-750, 2010
- 791 48. Spratt JA, von Fournier D, Spratt JS, et al: Decelerating growth and human breast  
792 cancer. *Cancer* 71:2013-9, 1993

- 793 49. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, et al: Breast cancer tumor growth  
794 estimated through mammography screening data. *Breast Cancer Res* 10:R41, 2008
- 795 50. Houssami N, Hunter K: The epidemiology, radiology and biological characteristics of  
796 interval breast cancers in population mammography screening. *NPJ Breast Cancer* 3:12, 2017
- 797 51. Zhang S, Ding Y, Zhou Q, et al: Correlation Factors Analysis of Breast Cancer Tumor  
798 Volume Doubling Time Measured by 3D-Ultrasound. *Med Sci Monit* 23:3147-3153, 2017
- 799 52. Cuzick J: Preventive therapy for cancer. *Lancet Oncol* 18:e472-e482, 2017
- 800 53. Chlebowski RT, Kuller LH, Prentice RL, et al: Breast cancer after use of estrogen plus  
801 progestin in postmenopausal women. *N Engl J Med* 360:573-87, 2009
- 802 54. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on  
803 breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative  
804 Randomized Trial. *JAMA* 289:3243-53, 2003
- 805 55. Engel J, Schubert-Fritschle G, Hölzel D: Hormone replacement therapy and elevated  
806 breast cancer risk: An artifact of growth acceleration? *MEDRXIV/2020/050708*, 2020
- 807 56. Bertucci F, Ng CKY, Patsouris A, et al: Genomic characterization of metastatic breast  
808 cancers. *Nature* 569:560-564, 2019
- 809 57. Pan H, Gray R, Braybrooke J, et al: 20-Year Risks of Breast-Cancer Recurrence after  
810 Stopping Endocrine Therapy at 5 Years. *N Engl J Med* 377:1836-1846, 2017
- 811 58. Hölzel D, Eckel R, Bauerfeind I, et al: Improved systemic treatment for early breast  
812 cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-  
813 year results from the Munich Cancer Registry. *J Cancer Res Clin Oncol* 143:1701-12, 2017
- 814 59. McGrath S, Antonucci J, Goldstein N, et al: Long-term patterns of in-breast failure in  
815 patients with early stage breast cancer treated with breast-conserving therapy: a molecular based  
816 clonality evaluation. *Am J Clin Oncol* 33:17-22, 2010
- 817 60. Smith TE, Lee D, Turner BC, et al: True recurrence vs. new primary ipsilateral breast  
818 tumor relapse: an analysis of clinical and pathologic differences and their implications in natural  
819 history, prognoses, and therapeutic management. *Int J Radiat Oncol Biol Phys* 48:1281-9, 2000
- 820 61. Colleoni M, Rotmensz N, Peruzzotti G, et al: Size of breast cancer metastases in  
821 axillary lymph nodes: clinical relevance of minimal lymph node involvement. *J Clin Oncol* 23:1379-89,  
822 2005
- 823 62. de Boer M, van Deurzen CH, van Dijck JA, et al: Micrometastases or isolated tumor  
824 cells and the outcome of breast cancer. *N Engl J Med* 361:653-63, 2009
- 825 63. Pedersen L, Gunnarsdottir KA, Rasmussen BB, et al: The prognostic influence of  
826 multifocality in breast cancer patients. *Breast* 13:188-93, 2004
- 827 64. O'Daly BJ, Sweeney KJ, Ridgway PF, et al: The accuracy of combined versus largest  
828 diameter in staging multifocal breast cancer. *J Am Coll Surg* 204:282-5, 2007
- 829 65. Hölzel D, Eckel R, Bauerfeind I, et al: Survival of de novo stage IV breast cancer  
830 patients over three decades. *J Cancer Res Clin Oncol* 143:509-19, 2017
- 831 66. Colleoni M, Sun Z, Price KN, et al: Annual Hazard Rates of Recurrence for Breast  
832 Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group  
833 Trials I to V. *J Clin Oncol* 34:927-35, 2016
- 834 67. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term  
835 clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 384:164-72, 2014
- 836 68. Robidoux A, Tang G, Rastogi P, et al: Lapatinib as a component of neoadjuvant  
837 therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised  
838 phase 3 trial. *Lancet Oncol* 14:1183-92, 2013
- 839 69. von Minckwitz G, Untch M, Blohmer JU, et al: Definition and impact of pathologic  
840 complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer  
841 subtypes. *J Clin Oncol* 30:1796-804, 2012
- 842 70. Fontein DB, Charehbili A, Nortier JW, et al: Efficacy of six month neoadjuvant  
843 endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II  
844 trial. *Eur J Cancer* 50:2190-200, 2014

- 845 71. Fentiman IS, Christiaens MR, Paridaens R, et al: Treatment of operable breast cancer  
846 in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified  
847 radical mastectomy. *Eur J Cancer* 39:309-16, 2003
- 848 72. Spring LM, Gupta A, Reynolds KL, et al: Neoadjuvant Endocrine Therapy for Estrogen  
849 Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol* 2:1477-1486,  
850 2016
- 851 73. Ellis MJ, Suman VJ, Hoog J, et al: Ki67 Proliferation Index as a Tool for Chemotherapy  
852 Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results  
853 From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). *J Clin Oncol* 35:1061-  
854 1069, 2017
- 855 74. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast  
856 cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl*  
857 *Cancer Inst* 97:1652-62, 2005
- 858 75. Cuzick J, Sestak I, Forbes JF, et al: Use of anastrozole for breast cancer prevention  
859 (IBIS-II): long-term results of a randomised controlled trial. *Lancet* 395:117-22, 2020
- 860 76. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer:  
861 an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. *Lancet*  
862 351:1451-67, 1998
- 863 77. Early Breast Cancer Trialists' Collaborative Group: Relevance of breast cancer  
864 hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-  
865 analysis of randomised trials. *Lancet* 378:771-84, 2011
- 866 78. Early Breast Cancer Trialists' Collaborative Group: Comparisons between different  
867 polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among  
868 100,000 women in 123 randomised trials. *Lancet* 379:432-44, 2012
- 869 79. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al: 11 years' follow-up of trastuzumab  
870 after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin  
871 Adjuvant (HERA) trial. *Lancet* 389:1195-1205, 2017
- 872 80. Welch HG, Prorok PC, O'Malley AJ, et al: Breast-Cancer Tumor Size, Overdiagnosis,  
873 and Mammography Screening Effectiveness. *N Engl J Med* 375:1438-1447, 2016
- 874 81. Jurrius P, Green T, Garmo H, et al: Invasive breast cancer over four decades reveals  
875 persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon.  
876 *Breast* 50:39-48, 2020
- 877 82. Hanna TP, King WD, Thibodeau S, et al: Mortality due to cancer treatment delay:  
878 systematic review and meta-analysis. *Bmj* 371:m4087, 2020
- 879 83. Delozier T, Switsters O, Genot JY, et al: Delayed adjuvant tamoxifen: ten-year results  
880 of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial). *Ann Oncol*  
881 11:515-9, 2000
- 882 84. Veronesi A, Miolo G, Magri MD, et al: Late tamoxifen in patients previously operated  
883 for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised  
884 study. *BMC Cancer* 10:205, 2010
- 885 85. Kim H, Kim CY, Park KH, et al: Clonality analysis of multifocal ipsilateral breast  
886 carcinomas using X-chromosome inactivation patterns. *Hum Pathol* 78:106-114, 2018
- 887 86. Mamtani A, Patil S, Stempel M, et al: Axillary Micrometastases and Isolated Tumor  
888 Cells Are Not an Indication for Post-Mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. *Ann*  
889 *Surg Oncol* 24:2182-8, 2017
- 890 87. Razavi P, Chang MT, Xu G, et al: The Genomic Landscape of Endocrine-Resistant  
891 Advanced Breast Cancers. *Cancer Cell* 34:427-438.e6, 2018
- 892 88. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al: 2 years versus 1 year of adjuvant  
893 trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.  
894 *Lancet* 382:1021-8, 2013
- 895 89. Pivot X, Romieu G, Debled M, et al: 6 months versus 12 months of adjuvant  
896 trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.  
897 *Lancet Oncol* 14:741-8, 2013

- 898 90. Petrelli F, Rulli E, Labianca R, et al: Overall survival with 3 or 6 months of adjuvant  
899 chemotherapy in Italian TOSCA Phase 3 Randomized Trial. *Ann Oncol*, 2020
- 900 91. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen  
901 to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:  
902 ATLAS, a randomised trial. *Lancet* 381:805-16, 2013
- 903 92. Curigiano G, Burstein HJ, E PW, et al: De-escalating and escalating treatments for  
904 early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary  
905 Therapy of Early Breast Cancer 2017. *Ann Oncol* 28:1700-1712, 2017
- 906 93. Burstein HJ, Lacchetti C, Anderson H, et al: Adjuvant Endocrine Therapy for Women  
907 With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. *J*  
908 *Clin Oncol* 37:423-438, 2019
- 909 94. Engel J, Schubert-Fritschle G, Emeny R, et al: Breast cancer: Are long-term and  
910 intermittent endocrine therapies equally effective? *J Cancer Res Clin Oncol*, 2020
- 911 95. Smith IE, Yeo B, Schiavon G: The optimal duration and selection of adjuvant  
912 endocrine therapy for breast cancer: how long is enough? *Am Soc Clin Oncol Educ Book*:e16-24, 2014
- 913 96. Peto R: Five years of tamoxifen--or more? *J Natl Cancer Inst* 88:1791-3, 1996
- 914 97. Minchinton AI, Tannock IF: Drug penetration in solid tumours. *Nat Rev Cancer* 6:583-  
915 92, 2006
- 916 98. Conte P, Frassoldati A, Bisagni G, et al: 9 weeks vs 1 year adjuvant trastuzumab in  
917 combination with chemotherapy: final results of the phase III randomized Short-HER study. *Ann*  
918 *Oncol*, 2018
- 919 99. Holohan C, Van Schaeybroeck S, Longley DB, et al: Cancer drug resistance: an  
920 evolving paradigm. *Nat Rev Cancer* 13:714-26, 2013
- 921 100. Jeselsohn R, Buchwalter G, De Angelis C, et al: ESR1 mutations-a mechanism for  
922 acquired endocrine resistance in breast cancer. *Nat Rev Clin Oncol* 12:573-83, 2015
- 923 101. Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in  
924 breast cancer. *Nat Rev Cancer* 9:631-43, 2009
- 925 102. Altrock PM, Liu LL, Michor F: The mathematics of cancer: integrating quantitative  
926 models. *Nat Rev Cancer* 15:730-45, 2015
- 927 103. Hershman DL, Wright JD: Comparative effectiveness research in oncology  
928 methodology: observational data. *J Clin Oncol* 30:4215-22, 2012
- 929 104. Concato J, Lawler EV, Lew RA, et al: Observational methods in comparative  
930 effectiveness research. *Am J Med* 123:e16-23, 2010

931